DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
Silver Spring MD 20993

BLA 125293/S-081

SUPPLEMENT APPROVAL
FULFILLMENT OF POSTMARKETING REQUIREMENTS

Crealta Pharmaceuticals LLC
500 W. Silver Spring Drive, Suite K-200
Glendale, WI 53217

Attention: John André
Senior Director, Regulatory Affairs

Dear Mr. André:

Please refer to your Supplemental Biologics License Application (sBLA), dated April 2, 2015, and received April 2, 2015, submitted under section 351(a) of the Public Health Service Act for Krystexxa (pegloticase) Injection, 8 mg/mL.

We acknowledge receipt of your amendments dated April 17, June 1 and 19 and July 8, 2015.

This Prior Approval supplemental biologics application proposes updates to section 8.1 (Pregnancy) and section 13.1 (Carcinogenesis, Mutagenesis, Impairment of Fertility) of the Package Insert (PI) to include the results of non-clinical studies. These studies were conducted to address Postmarketing Requirement Studies (PMR) 2569-2, 2569-3, and 2569-4 listed in the approval letter for BLA 125293/0 dated September 14, 2010.

APPROVAL & LABELING

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit, via the FDA automated drug registration and listing system (eLIST), the content of labeling [21 CFR 601.14(b)] in structured product labeling (SPL) format, as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm, that is identical to the enclosed labeling (text for the package insert and text for the Medication Guide) and include the labeling changes proposed in any pending "Changes Being Effected" (CBE) supplements. Information on submitting SPL files using eLIST may be found in the guidance for

industry titled “SPL Standard for Content of Labeling Technical Qs and As” at http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf.

The SPL will be accessible via publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that includes labeling changes for this BLA, including pending “Changes Being Effected” (CBE) supplements, for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 601.12(f)] in MS Word format that includes the changes approved in this supplemental application.

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because none of these criteria apply to your application, you are exempt from this requirement.

FULFILLMENT OF POSTMARKETING REQUIREMENTS

We have received your submissions dated June 14, September 27 and October 31, 2012, containing the final reports for the following postmarketing requirements listed in the September 14, 2010, approval letter for BLA 125293/0.

2569-2 Conduct a male and female fertility study in rats per ICH-S5A and ICH-S5B guidances.

2569-3 Conduct an embryo-fetal development study in the rabbit model (Segment 2) according to ICH-S5A guidance.

2569-4 Conduct a peri-natal and post-natal development stud y in the rat model (Segment 3).

We have reviewed your submissions and conclude that the above requirements were fulfilled.

We remind you that there are postmarketing requirements listed in the September 14, 2010, approval letter that are still open.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved BLA (in 21 CFR 600.80 and in 21 CFR 600.81).

If you have any questions, call Carol F. Hill, Senior Regulatory Health Project Manager, at (301) 796-1226.

Sincerely,

{See appended electronic signature page}

Sally Seymour, MD
Deputy Director for Safety
Division of Pulmonary, Allergy, and Rheumatology Products
Office of Drug Evaluation II
Center for Drug Evaluation and Research

ENCLOSURE(S):
Content of Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

SALLY M SEYMOUR
07/17/2015